Trial Profile
A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Acronyms JIA-2
- Sponsors Bristol-Myers Squibb
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 23 Sep 2022 Last checked against the ClinicalTrials.gov record.
- 08 Sep 2022 Planned End Date changed from 29 Dec 2023 to 31 Mar 2023.